EL7.AI
StocksMedium•27 August 2026•
2 min read

Barclays Raises Agilent Price Target to $175 Following Strong Q3 Results

Key Facts

1Barclays raised Agilent Technologies' price target to $175 from $150.
2The company reported an 8% year-over-year revenue increase to $1.88 billion for Q3.
3Agilent raised its annual profit forecast with anticipated revenue growth between 6.5% and 7.5%.

In a move reflecting strong operational performance within the healthcare sector, Barclays analyst Luke Sergott raised the price target for Agilent Technologies to $175 from $150. This revision follows the company's reported 8% year-over-year revenue increase to $1.88 billion for the third quarter, accompanied by an 18% rise in earnings per share. Furthermore, Agilent raised its annual profit forecast, now anticipating revenue growth between 6.5% and 7.5%, signaling management's confidence in continued business momentum.

According to analyst data, the Life Sciences and Diagnostics segment, the company's core business, showed exceptional strength as operating margins expanded by 600 basis points to 23.5%. This growth comes amid increasing demand for laboratory tools and drug development equipment, which contributed to enhanced profitability and operating efficiency. These results highlight Agilent's ability to achieve sustained growth across all business segments in a competitive market environment.

The stock A stood at $152.955 at the close of August 26, 2026, with the session's trading range between $152.895 and $154.84 per market data. Investors are monitoring the stock's response to these positive price target revisions, especially as the company continues to execute its growth strategy in medical diagnostics. With no immediate upcoming economic catalysts in the calendar, focus remains on the company's fundamentals and updated profit guidance.